Patrick Frayssinet

World Vaccine Congress Washington Speaker Interview: Dr Patrick Frayssinet

|| Dr Patrick Frayssinet, R&D Director, URODELIA We have interviewed a few of the speakers from World Vaccine Congress Washington, taking place on 10-12 April 2017 in Grand Hyatt Washington. This is the 1st of the interview series, stay connected for more. Q1: The most promise opportunities in the veterinary vaccines space are? A: One of the most promise opportunities …

Advaxis Secures $23 Million Financing

Last week, Advaxis, Inc. (a clinical-stage biotechnology company developing cancer immunotherapies on its proprietary Lm-LLO platform technology), announced that a combined $23 million of purchase agreements was raised, worth approximately 3.1 million shares, at a price of $7.50 per share from several institutional investors. The investors include Adage Capital Management, L.P. Broadfin Capital LLC, Sectoral Asset Management, Cormorant Asset Management and …

World Vaccine Congress Washington 2015

Download: ‘Vaccine Insights’ eBook, interviews with the leaders of the vaccine industry

The world of vaccine development is changing. Personalised medicine is making huge waves in the industry, and from this we have seen the rise of therapeutic vaccines for diseases such as cancer. Alongside this, the Ebola crisis has caused all stakeholders to re-evaluate the processes for research and manufacture of vaccines to ensure that they can roll them out as …

CFDA approves production of the first Sabin IPV

China Food and Drug Administration (CFDA) has approved the production of the first inactivated poliomyelitis vaccine made from inactivated Sabin strains (Sabin IPV). It was researched and developed by the Institute of Medical Biology, Chinese Academy of Medical Sciences. Poliomyelitis, often called polio or infantile paralysis, is an infectious disease caused by the poliovirus. It is a virus-transmitted disease that …

Geographical risk of Dengue and clinical studies conducted by Sanofi Pasteur

Making Dengue the Next Vaccine-Preventable Disease

Each year, there are approximately 50 million Dengue infections and an estimated 500,000 individuals are hospitalized with Dengue haemorrhagic fever. There have been attempts to develop a Dengue vaccine since the 1940s, but due to the limited appreciation of its global disease burden and market value, the industry’s interest deteriorated in the 20th century.   In 2013, the WHO ranked …

Ebola Hemorrhagic Fever, www.CDC.gov

Looming Pressure on Pharma as the Spread of Ebola Continues

When will a vaccine become available for Ebola? Killing over 8,000 people in West Africa since last year and still spreading, the need for a prophylactic Ebola vaccine is becoming increasingly important. Companies are racing to bring a safe vaccine to market and with the current pace of the epidemic in Liberia, Sierra Leone and Guinea, the demand for Ebola …